Home › Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...
 

Keywords :   


Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...

2013-11-02 15:57:50| Biotech - Topix.net

Gilead Sciences, Inc. today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus infection among patients co-infected with HIV.

Tags: results phase announces gilead

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Storm Surge Watch/Warning Map
05.07Tropical Storm Beryl Graphics
05.07Tropical Storm Beryl Forecast Discussion Number 29
05.07Tropical Storm Beryl Wind Speed Probabilities Number 29
05.07Tropical Storm Beryl Forecast Advisory Number 29
05.07Tropical Storm Beryl Public Advisory Number 29
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Tropical Depression Aletta Graphics
More »